- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01319110
Coenzyme Q10 in Post-Cardiac Arrest Cerebral Resuscitation
Specific Aim #1: To determine if levels of CoQ10 are low post-cardiac arrest (CA). We will perform a prospective trial with the primary endpoint of describing the prevalence of low serum CoQ10 levels.
Specific Aim #2: To determine if CoQ10 levels in post-CA patients can be increased with the administration of exogenous CoQ10.. We will perform a randomized control trial (RCT) of post-CA patients with the secondary endpoint of comparing CoQ10 levels among those randomized to CoQ10 supplementation vs placebo.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Cardiac arrest (CA) occurs in nearly 350,000 patients in the U.S. each year with an estimated mortality of 60% in those surviving the initial arrest. Moreover, the overall prognosis for survivors is often limited by neurologic injury. Two randomized control trials (RCTs) have demonstrated that therapeutic hypothermia (TH) after CA improves survival and reduces neurologic morbidity. As a result of these studies, TH has become the standard of care in post-CA patients. The mechanism of action for TH is hypothesized to be a reduction in cerebral oxygen consumption that occurs following an ischemia-reperfusion injury. Another similar potential target following ischemia-reperfusion injury is mitochondrial function in the injured brain cells and attenuation of potentially damaging oxygen-free radicals. Specifically, optimizing mitochondrial function and reducing oxygen free radicals may enhance cellular function and mitigate cellular injury thereby leading to improved neurologic outcomes. Coenzyme Q10 (CoQ10) is an essential mitochondrial co-factor and free radical scavenger that has been found to have neuroprotective effects in various neurodegenerative disorders such as Parkinson's disease and Huntington's disease. Whether CoQ10 can provide neuroprotection in acute ischemia-reperfusion injury remains less clear, but has been recognized by the American Heart Association as a potentially promising neuroprotective agent. We hypothesize that the administration of exogenous CoQ10 will raise serum concentrations of CoQ10 and as such may mitigate the adverse effects of the post-CA ischemia-reperfusion injury on the brain by optimizing mitochondrial function and reducing oxygen-free radicals. We support this hypothesis by the following:
- Ischemia-reperfusion injury disrupts normal mitochondrial function and increases O2 free radicals.
- CoQ10 has been found to attenuate the effects of ischemia-reperfusion injury through optimizing mitochondrial function and mitigation of cellular apoptosis.
- CoQ10 has neuroprotective effects in other neurodegenerative disorders.
- Our group has unpublished preliminary data showing low CoQ10 levels in a majority of patients with septic shock, and that lower CoQ10 levels are significantly associated with multiple markers of the inflammatory cascade.
- A pilot human trial in post-CA patients demonstrated a reduction in mortality and trend toward reduction in neurologic morbidity.
To test our hypothesis, we propose the following pilot study as proof of concept in preparation for a larger multicenter trial powered toward neurologic outcome and mortality. This pilot study will allow for a more informed power analysis for a larger trial, provide proof of concept for enrollment and administration of therapy, examine the time-frame for drug absorption into serum, and evaluate for tolerability.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patients (age > 18 years)
- Comatose after CA with subsequent return of spontaneous circulation
Exclusion Criteria:
- Comatose status prior to CA
- CoQ10 therapy within one month prior to CA
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CoenzymeQ10
Patients will receive CoenzymeQ10 200mg three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first).
CoQ10 will be given through pre-existing NG or OG tube, and mixed with 20 ml of chocolate Ensure so as to blind investigators and staff.
|
Patients will receive CoQ10 200mg three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first).
CoQ10 will be given through pre-existing NG or OG tube, and mixed with 20 ml of chocolate Ensure so as to blind investigators and staff.
Other Names:
|
Placebo Comparator: Placebo
Patients will receive 20 ml chocolate Ensure (as a placebo) three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first).
Placebo will be given through pre-existing NG or OG tube.
|
Patients will be given Chocolate Ensure via NG/ OG 3x daily as a placebo.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of Low Serum CoQ10 Levels in Cardiac Arrest Patients
Time Frame: Baseline
|
The primary outcome will be describing the prevalence of low serum CoQ10 levels compared to standard laboratory control values.
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of Serum CoQ10 Levels Randomized to Supplementation vs. Placebo
Time Frame: 1 year
|
The secondary outcome will be to compare serum CoQ10 levels among those post-arrest patients randomized to CoQ10 supplementation vs placebo.
|
1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Michael N Cocchi, MD, Beth Israel Deaconess Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2010P000362
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiac Arrest
-
Italian Resuscitation CouncilUnknownOut-Of-Hospital Cardiac Arrest | In-hospital Cardiac ArrestItaly
-
Australian and New Zealand Intensive Care Research...Ambulance VictoriaNot yet recruitingOut of Hospital Cardiac Arrest
-
University Medical Centre MariborRecruiting
-
IRCCS Policlinico S. MatteoOslo University Hospital; University of the Basque Country (UPV/EHU); The Hospital...CompletedOut-Of-Hospital Cardiac ArrestItaly, Norway, Spain
-
Lithuanian University of Health SciencesEgle Vaitkaitiene; Dinas Vaitkaitis; Asta Krikscionaitiene; Ilona Kajokaite; Nerijus...CompletedOut-Of-Hospital Cardiac ArrestLithuania
-
Ceric SàrlAbbottTerminatedOut of Hospital Cardiac ArrestBelgium, France, Serbia
-
Prehospital Center, Region ZealandCompletedOut-Of-Hospital Cardiac Arrest
-
Karolinska InstitutetSwedish Heart Lung FoundationCompletedCardiac Arrest | Out of Hospital Cardiac ArrestSweden
-
Karolinska InstitutetVastra Gotaland Region; SOS Alarm Sverige AB; Everdrone AB; Aviation capacity resources... and other collaboratorsCompleted
-
Brno University HospitalTerminatedOut-Of-Hospital Cardiac ArrestCzechia
Clinical Trials on Coenzyme Q10
-
University of SumerCompletedMale InfertilityIraq
-
University of ShizuokaCompletedHemodialysis | Chronic Renal FailureJapan
-
Central Hospital, Nancy, FranceCompletedCyclic Vomiting SyndromeFrance
-
Columbia UniversityNational Institute of Neurological Disorders and Stroke (NINDS)CompletedAmyotrophic Lateral Sclerosis | Lou Gehrig's DiseaseUnited States
-
Hadassah Medical OrganizationUnknown
-
Peter HumaidanCompleted
-
Johns Hopkins UniversityNational Institute of Neurological Disorders and Stroke (NINDS)CompletedHuntington's DiseaseUnited States
-
Technische Universität DresdenDeutsche Parkinson-Vereinigung e.V.; MSE Pharmazeutika GmbH, Bad HomburgCompleted
-
Mclean HospitalNational Alliance for Research on Schizophrenia and DepressionCompleted
-
National University Hospital, SingaporeCompletedParkinson DiseaseSingapore